Lesinurad Combined With Allopurinol: Randomized, Double-Blind, Placebo-Controlled Study in Gout Subjects With Inadequate Response to Standard of Care Allopurinol (A US-based Study)

In this RCT (n=603), lesinurad at 200-mg and 400-mg doses, added to allopurinol, significantly increased proportions of individuals achieving serum urate (sUA) target versus allopurinol alone by month 6 (54.2%, 59.2%, and 27.9%, respectively, P<0.0001).

Lesinurad is a once-daily inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body.

In this study, lesinurad did not show significant superiority in secondary endpoints: rates of gout flares and complete tophus resolution.